INSMED INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
INSMED INC (INSM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $68.55 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-19
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $29.51, a 114.31% increase year-over-year.
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $13.77, a 12.18% decline year-over-year.
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $15.68, a 6.83% decline year-over-year.
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $16.83, a 14.91% decline year-over-year.
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $68.55, a 110.34% increase from fiscal 2024.
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $32.59, a 61.34% increase from fiscal 2023.
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $20.20, a 3.30% decline from fiscal 2022.
- INSMED INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $20.89, a 30.78% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $68.55 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $32.59 10-K · filed 2025-02-20 | |||
| 2023-12-31 | $20.20 10-K · filed 2025-02-20 | |||
| 2022-12-31 | $20.89 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $30.18 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $24.12 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $15.02 10-K · filed 2022-02-17 | |||
| 2018-12-31 | $27.63 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $28.57 10-Q · filed 2018-10-30 | |||
| 2018-06-30 | $29.22 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $29.51 10-Q · filed 2018-05-02 | |||
| 2017-12-31 | $15.92 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $15.42 10-Q · filed 2017-11-02 | |||
| 2017-06-30 | $15.45 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $13.77 10-Q · filed 2017-05-03 | |||
| 2016-12-31 | $12.96 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $12.89 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $12.94 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $15.68 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $20.45 10-K · filed 2018-02-23 | |||
| 2015-09-30 | $20.68 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $20.54 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $16.83 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $16.10 10-K · filed 2017-02-23 | |||
| 2014-09-30 | $16.11 10-Q · filed 2014-11-06 | |||
| 2014-06-30 | $16.22 10-Q · filed 2014-08-06 | |||
| 2014-03-31 | $19.78 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | $10.53 10-K · filed 2016-02-25 | |||
| 2013-09-30 | $9.84 10-Q · filed 2013-11-05 | |||
| 2013-06-30 | $9.37 10-Q · filed 2013-08-06 | |||
| 2013-03-31 | $6.85 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | $4.12 10-K · filed 2015-02-27 | |||
| 2012-09-30 | $3.63 10-Q · filed 2012-11-07 | |||
| 2012-06-30 | $3.48 10-Q · filed 2012-08-07 | |||
| 2011-12-31 | $3.77 10-K · filed 2014-03-06 | |||
| 2010-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |